People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Pharma, Other Health Care, Retailing, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Intrinsic Therapeutics Inc | — | Pharma | Series C | $219.5M | $594.7M | 2012 |
| Moximed, Inc | — | Other Health Care | Series C | $187.8M | $499.3M | 2009 |
| ExploraMed NC7, Inc. | — | Other Health Care | Series C | $181.5M | $751.6M | 2015 |
| Neotract Inc | — | Other Health Care | Series C | $117.5M | $293.0M | 2012 |
| Coravin, Inc. | — | Retailing | Series B | $68.8M | $25.7M | 2013 |
| Ceterix Orthopaedics, Inc. | — | Other Health Care | Series B | $54.4M | $510.5M | 2012 |
| Nuelle, Inc. | — | Other Health Care | Series B | $36.6M | $156.2M | 2014 |
| Vibrynt, INc | — | Other Health Care | Series A | $14.3M | $55.5M | 2012 |
| X9, Inc. | — | Other | Series A | $13.7M | $25.6M | 2022 |
| ExploraMed IV, L.L.C. | — | Other | Series A | $6.6M | $99.9M | 2011 |
Joshua Makower at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Joshua Makower on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ryan Drant | 7 | 24 |
| John Nehra | 5 | 11 |
| Robert Anderson | 4 | 24 |
| ROBERT CROCE | 4 | 7 |
| Robert W. Croce | 4 | 7 |
| Joshua W. Makower | 4 | 4 |
| Robert K. Anderson | 3 | 6 |
| David Amerson | 3 | 5 |
| Ryan W. Drant | 3 | 4 |
| Kevin Sidow | 2 | 7 |
| Earl Bright | 2 | 2 |
| John W. Nehra | 2 | 2 |
| Christopher Gleason | 1 | 35 |
| Kirk Nielsen | 1 | 13 |
| Peter Bisgaard | 1 | 9 |
| Jeani Delagardelle | 1 | 8 |
| Henry A. Plain, Jr. | 1 | 7 |
| Michael Carusi | 1 | 7 |
| Heather Preston | 1 | 6 |
| Charles Warden | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.